Takeda Consumer Healthcare Company Limited starts its business

Osaka and Tokyo, Japan, April 3, 2017 — Takeda Pharmaceutical Company Limited [TSE: 4502] (Headquarters: Osaka, Japan; "Takeda") and Takeda Consumer Healthcare Company Limited (Headquarters: Tokyo, Japan; "TCHC") today announced that TCHC succeeded the business of Takeda’s Japan Consumer Healthcare Business Unit ("JCHBU") and started its business on April 1, 2017 as the new company.

JCHBU was a business unit of Takeda which operated the consumer healthcare business, mainly in Japan. JCHBU has been realizing sustained growth by focusing on over-the-counter medicines including Alinamin, Benza, and a health food named Midori-no-Shukan. The market environment surrounding the consumer healthcare business is constantly changing, and customers’ needs are becoming more and more diversified. TCHC will have a more agile business model to promptly meet environmental changes and customer’s needs in the consumer health care market, by succeeding the business of JCHBU and running the business independently as the new company.

Masashi Sugimoto, President, TCHC said “With the start of TCHC’s business, it has become possible more than ever for us to promptly meet the rise of customers' health consciousness and their diversifying needs. From now on, we will continue to contribute to better health for people through our brands such as Alinamin, Benza, and Midori-no-Shukan in the field of Self Care and Self Medication, at the same time, aim to become a leading company in the consumer healthcare markets of the Asian region, focusing primary on Japan.”

* Details about the establishment of TCHC, see the press release on February 3, 2016.
* Details about the succession by splitting off (simple absorption-type split) of JCHBU, see the press release on February 20, 2017.

 [Outline of Takeda Consumer Healthcare Company Limited]

(1)    Company name

Takeda Consumer Healthcare Company Limited

(2)    Location

8-2, Marunouchi 1-chome, Chiyoda-ku, Tokyo, Japan

(3)    Representative

President: Masashi Sugimoto

(4)    Scope of business

Research & development, manufacturing, sales and marketing of over-the-counter products, quasi-drugs, etc.

(5)    Capital

490 million yen

(6)    Date established

April 15, 2016

(7)    Fiscal year end

March 31

(8)    Major shareholders and ratio of shares held

Takeda Pharmaceutical Company Limited 100%

For details, see http://www.takeda-chc.co.jp/

 ### 


Media Contact

Takeda Pharmaceutical Company Limited
Ai Yoshikawa
Corporate Communications
Tel: +81-3-3278-3004
E-mail: ai.yoshikawa@takeda.com

Takeda Consumer Healthcare Company Limited
Masato Nagata
Corporate Communications
Tel: +81-3-6212-8502
E-mail: masato.nagata@takeda.com